Biotech Values

[DewDiligence]

Clarification to #msg-95173688:

I’ll update the relevant posts in the MNTA ReadMeFirst to account for the termination of the third FoB compound (M511).

The above should have said Baxter’s termination of M511 within the BAX-MNTA collaboration rather than termination of M511 per se. MNTA’s 8-K filing today says that MNTA will continue development of M511 without Baxter.

I previously speculated that M511 is an FoB for Erbitux.